Table 3.
Median survival outcomes of immune checkpoint inhibitors in patients with glioblastoma or brain metastases.
| Variable | Glioblastoma | Brain Metastases | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | NSCLC | All | |||||||
| IPI | NIVO | PEMBRO | IPI + NIVO | PEMBRO | NIVO | ATEZO | All | ||
| Median Intracranial PFS | 2.1 mo | 1.2–3.0 mo | 2.3–2.5 mo | N.A. | N.A. | N.A. | 3.9 mo | N.A. | 2.7 mo |
| Median PFS | - | 3.0–3.1 mo | N.A. | 2.0–5.2 mo | 2.9 mo | N.A. | 1.6–3.0 mo | 2.5 mo | 3.0 mo |
| Median OS | 7.3 mo | 3.3–14.0 mo | 5.1–18.5 mo | 17.0–20.4 mo | 17.4 mo | 7.7 mo | 2.8–9.0 mo | 6.8 mo | 8.0 mo |
ATEZO: Atezolizumab; PFS: Progression-free survival; OS: Overall survival; IPI: Ipilimumab; NIVO: Nivolumab; PEMBRO: Pembrolizumab. N.A.: Not available; mo: Months.